Another ADHD failure cements Aevi's penny stock status - Endpoints News

Another ADHD failure cements Aevi's penny stock status  Endpoints NewsAevi Genomic Medicine's genetic approach to treating ADHD was expected to ascend its lead drug to great heights in the commonly diagnosed nuerobehavioral ...